spacer
spacer
top decoration A to Z Index MCG HomeSite Search
VBC Header
VBC Home spacer
white corner left spacer
spacer FACULTY spacer
spacer
spacer Core Faculty Right Arrow
spacer
spacer Associate Members spacer
spacer
spacer
spacer RESEARCH spacer
spacer
spacer Funding & Grants spacer
spacer
spacer Seminars spacer
spacer
spacer Cardiovascular Journals spacer
spacer
spacer
spacer TEACHING spacer
spacer
spacer Graduate Programs spacer
spacer
spacer Post Doc Studies spacer
spacer
spacer Trainee Awards spacer
spacer
spacer Training Grants spacer
spacer
spacer
spacer FACILITIES spacer
spacer
spacer Campus Overview spacer
spacer
spacer Core Labs spacer
spacer
spacer
CORE FACULTY : Professional Biography Arrow Read More Biographies
spacer
Photo Placer spacer
Rudolph Lucas, Ph.D.
Phone: (706) 721-9470
Fax: (706) 721-9799
Office: CB 3713 / Lab: CB-



Research Interests

Pulmonary edema is a significant medical problem worldwide and is defined as a pathological dysbalance between fluid extravasation and fluid reabsorption in the alveoli and capillaries. This pathology can be caused by i) an increased capillary pressure in the lungs (cardiogenic/hydrostatic edema);
ii) an increased permeability or disruption of the alveolar epithelial-endothelial barrier (permeability edema) and
iii) a dysregulated expression or function of crucial ion channels in type II alveolar epithelial cells (AEC) implicated in lung liquid clearance, such as the apically expressed epithelial sodium channel ENaC and the basolaterally expressed Na+-K+-ATP-ase.
As a consequence, a reduction of lung compliance and an impaired gas exchange may occur, leading to hypoxemia and respiratory acidosis. In case of cardiogenic edema, a causal therapy of the underlying disease is often preceded by a symptomatic treatment of the impaired gas exchange, e.g. by means of non-invasive ventilation, paralleled by efficient medical interventions. In the clinics, hydrostatic edema is mostly a consequence of heart failure, whereas permeability edema is mostly a consequence of acute lung inflammation, as can be observed e.g. in the adult respiratory distress syndrome (ARDS) and during ischemia-reperfusion induced acute lung injury. There is accumulating evidence that the capacity of the lung to clear edema liquid is essential for outcome in both cardiogenic and non-cardiogenic pulmonary edema. Patients with ARDS have a dramatically reduced life expectancy when their fluid reabsorption capacity is impaired. Apart from strategies to optimize ventilation procedures, currently no standard therapy exists for permeability edema. Moreover, also viral and bacterial infections can induce a change in the expression or function of ENaC. Therefore, the search for substances able to reduce the endothelial hyperpermeability and/or restore the sodium uptake in type II AEC is important. Our data from flooded rat and mouse lung models, giving rise to hydrostatic edema, have indicated that the pro-inflammatory cytokine Tumor Necrosis Factor (TNF), which is induced during bacterial and viral infection, has a dichotomous role in lung liquid clearance during hydrostatic edema, with its receptor binding sites inhibiting alveolar liquid clearance and its lectin-like domain, mimicked by the 17 amino acid TIP peptide, rather activating this activity (Fig.1). Apart from its protective role in hydrostatic edema, our recent data have also indicated a preventive activity of the TIP peptide in rat and mouse models of permeability edema. Therefore, unraveling the mechanism of the protective action of the lectin-like domain of TNF during pulmonary permeability edema could provide valuable information for the development of a standard therapy. Fig. 1. Dichotomous role of TNF in lung liquid clearance. TNF's receptor binding sites, which can be blocked by the soluble TNF receptors, were shown to inhibit edema reabsorption in flooded rat lungs, whereas the cytokine's spatially distinct lectin-like domain, which can be inhibited by the oligosaccharide N,N'-diacetylchitobiose, rather activates lung liquid clearance.

spacer
spacer
spacer

Current Projects

Introduction

Streptococcus pneumoniae, a commensal of the human nasopharynx, is a major cause of community-acquired pneumonia, leading in a multitude of cases to pneumococcal sepsis. Infections with S. pneumoniae have accounted historically for more morbidity and mortality than any other bacterium. Moreover, the increasing prevalence of antibiotic resistance necessitates the development of novel therapeutic strategies to combat pneumonia. Acute lung injury (ALI) and acute respiratory distress syndrome ARDS) are sentinel features of the septic lung failure in patients with pneumogenic sepsis. Bacterial virulence factors, such as pneumolysin (PLY) secreted by S. pneumoniae, contribute to the transition from pneumonia to ALI to sepsis and finally to death. Apart from infections with S. pneumoniae, also Listeria monocytogenes infections, which mostly start as an oral infection caused by contaminated food, can cause severe lung complications in individuals having pre-disposing conditions, such as age, pregnancy, cancer, chronic diseases or organ transplantation. In this case, Listeriolysin O (LLO), a cholesterol-dependent cytolysin with homology to PLY and Streptolysin O, is the main virulence factor and can cause permeability edema. LLO directly increases epithelial and endothelial permeability and, like PLY, induces a strong inflammatory response, which can cause a dysfunction in ion channels implicated in alveolar fluid clearance. In view of their crucial role in bacterial virulence and their profound effects on the immune system of the host, LLO and PLY can thus be considered as model toxins for G+ infection-associated acute lung injury and permeability edema, which still result in high mortality.

1. Inhibitory activity of the TIP peptide in exotoxin-induced endothelial hyperpermeability.

In this project, we propose to further unravel and evaluate the protective mechanisms of the lectin-like domain of TNF in LLO- and PLY-induced models of permeability edema. Since the lectin-like domain of TNF is able to prevent endothelial hyperpermeability induced by LLO and PLY in monolayers of primary human lung microvascular endothelial cells, as measured in the electrical cell-substrate impedance device (Applied Biophysics), one part of this project aims at unraveling its protective mechanism., using state-of-the art molecular biology and immunocytochemistry approaches, thereby concentrating on actions of the TIP peptide on cytoskeletal changes induced by exotoxins in endothelial cells.

2. Role of the lectin-like domain of TNF in the regulation of sodium transporters in type II alveolar epithelial cells.

During the course of pulmonary diseases, such as during L. monocytogenes and S. pneumoniae infection-associated ALI, the alveolar space, as well as the interstitium are sites of intense inflammation. During this inflammatory process, proinflammatory substances such as TNF, IL-1beta and TGF-beta are produced locally. Interestingly, the occurrence of an inflammation can have profound effects on the functioning of ion transporters. Indeed, pro-inflammatory cytokines, such as TNF and IL-1 beta have been recently shown to influence under certain inflammatory conditions epithelial sodium uptake. Moreover, TNF was shown to directly promote edema formation, by means of by means of decreasing transendothelial resistance, inducing the production of reactive oxygen species in lung epithelial cells, or inducing ventilator-induced lung injury. In view of the previously demonstrated protective effect of the TNF-derived TIP peptide in LLO- and PLY-induced acute lung injury, as assessed by measuring the lung wet-to-dry ratio, we will also investigate whether this substance can restore the dysregulated lung liquid clearance under these conditions, thereby concentrating on the regulation of ENaC, in view of our observation that the specific ENaC inhibitor amiloride blocks the activity of the TIP peptide. To this purpose we will investigate gene and protein expression of the ENaC subunits in LLO/PLY-treated primary airway epithelial cells and in the H441 cell line, as well as the expression and activation status of ENaC regulators.

3. Relevance of the lectin-like domain of TNF in exotoxin-induced acute lung injury in vivo.

We have generated Triple mTNF knock-in C57BL6 mice, expressing a T104AE106AE109A mutant of mouse TNF that has lost its lectin-like activity, but has retained the TNF receptor-mediated effects, in order to investigate the physiological role of this TNF domain in TNF-mediated effects during G+-induced acute lung injury.

The results from these studies can give important information about alternative activation mechanisms of edema reabsorption during G+ infection and can thus contribute to the development of alternative therapeutic strategies for the treatment of permeability edema.

spacer
spacer
spacer

Grant Support as Principal Investigator

New investigator
spacer
spacer
spacer
Lab

Guang Yang, PhD: Research Associate

Chenling Xiong, International Exchange Graduate Student

Aluya Oseghale, International Exchange Pre-graduate Student
spacer
spacer
spacer

Honors and Awards

  •  
spacer
spacer
spacer
Invited Speaker


spacer
spacer
spacer
Selected Publications

Lucas, R. Recent advances on the role of the endothelium in pulmonary function and disease. Vascul Pharmacol. 2008 Jul 19. [Epub ahead of print]
Hundsberger, H, Verin A, Wiesner C, Pflueger M, Dulebo A, Schuett W, Maennel D, Wendel A and Lucas R. TNF: a moonlighting protein at the interface between cancer and infection. Frontiers in Biosc. 2008, 13:5374-86.

Latta M; Kuenstle G; Lucas R; Hentze H and Wendel A. ATP-dependent carbohydrates prevent TNF Receptor 1-dependent apoptotic and necrotic liver injury in mice. JPET 2007. 321(3): 1-9.

Lucas R; Hundsberger H; Braun C; Wendel A; Chakraborty T; Wiesner C and Hamacher J. The TNF-derived TIP peptide: a potential anti-edema drug. Letters in Drug Discovery and Design. 2007, 4(5):.336-340.

Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, Boneberg EM. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. 2006. Br J Cancer; 94(4):524-531.

Braun, C; Hamacher, J; Morel, D; Wendel, A; and Lucas R. Dichotomal Role of TNF in Experimental Pulmonary Edema Reabsorption. 2005. Journal of Immunology 175(5). 3402-3408.

Kresse, M; Latta, M; Kunstle, G; Riehle H-M; van Rooijen, N; Hentze, H; Tiegs, G; Biburger, M; Lucas, R. and Wendel A. Kupffer Cell expressed Membrane-Bound TNF mediates Melphalan hepatotoxicity via activation of both TNF Receptors. 2005. Journal of Immunology 175(6).4076-4083.

Weiller, M; Latta, M; Kresse, M; Lucas, R and Wendel A. Toxicity of nutritionally available selenium compounds in primary and transformed hepatocytes. Toxicology 2004, 201(1-3):21-30.

Elia, N; Tapponnier, M; Matthay, MA; Hamacher, J; Pache, J-C; Bründler, MA; Totsch, M; De Baetselier, P; Fransen, L; Fukuda, N; Morel, DR and Lucas R. Identification of the alveolar edema reabsorption activity of murine Tumor Necrosis Factor. AJRCCM 2003, 168: 1043-1050 (editorial in November 1st issue)

Xu, J; Lucas, R; Schuchmann, M; Kühnle, S; Meergans, T; Barreiros, AP; Lohse, A; Otto, G and Wendel A. GM-CSF restores innate, but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in vitro. J. Immunol. 2003, 171: 938-947.

Hamacher, J; Lucas, R; Lijnen, HR; Buschke, S; Dunant, Y; Wendel , A; Grau, GE; Suter, PM and Ricou B. Tumor necrosis factor and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar lavages of patients with acute respiratory distress syndrome. AJRCCM 2002; 166: 651-656.

Lucas, R; Lijnen, HR; Suffredini, AF; Pepper, MS; Steinberg, KP; Martin, TR and Pugin J. Increased angiostatin levels in bronchoalveolar lavage fluids from ARDS patients and from human volunteers after lung instillation of endotoxin. Thrombosis and Haemostasis. 2002; 87: 966-972.

Fukuda, N; Jayr, C; Lazrak, A; Wang, Y; Lucas, R; Matalon, S; Matthay, MA. Mechanisms of TNF-stimulation of amiloride sensitive sodium transport across the alveolar epithelium in vivo and epithelial cells in vitro. Am. J. Physiol. 2001; 280(6): L1258-L1265.

Lucas, R; Montesano, R; Pepper, MS; Hafner, M; Sablon, E; Dunant, Y; Grau, GE; De Baetselier, P; Maennel, D; Fransen L. Lectin-deficient TNF mutants display comparable anti-tumour but reduced pro-metastatic potential as compared to the wild-type molecule. Int J Cancer. 2001; 15;91(4):543-549.

Lucas, R; Tacchini-Cottier, F; Guler, R; Vesin, D; Jemelin, S; Olleros, ML; Marchal, G; Browning, JL; Vassalli, P; Garcia I. A role for lymphotoxin beta receptor in host defense against Mycobacterium bovis BCG infection. Eur. J. Immunol. 1999; 29(12):4002-4010.

Favre, N; Da Laperousaz, C; Ryffel, B; Weiss, NA; Imhof, BA; Rudin, W; Lucas, R; Piguet PF. Role of ICAM-1 (CD54) in the development of murine cerebral malaria. Microbes Infect. 1999; 1(12):961-968.

van der Goot, FG; Pugin, J; Hribar, M; Fransen, L; Dunant, Y; De Baetselier, P; Bloc, A; Lucas R. Membrane interaction of TNF is not sufficient to trigger increase in membrane conductance in mammalian cells. FEBS Lett. 1999; 460(1):107-111.

Hribar, M; Bloc, A; van der Goot, FG; Fransen, L; De Baetselier, P; Grau, GE; Bluethmann, H; Matthay, MA; Dunant, Y; Pugin, J; Lucas R. The lectin-like domain of tumor necrosis factor-alpha increases membrane conductance in microvascular endothelial cells and peritoneal macrophages. Eur. J. Immunol. 1999; 29(10):3105-3111.

Truyens, C; Torrico, F; Lucas, R; De Baetselier, P; Buurman, WA; Carlier, Y. The endogenous balance of soluble tumor necrosis factor receptors and tumor necrosis factor modulates cachexia and mortality in mice acutely infected with Trypanosoma cruzi. Infect Immun. 1999; 67(11):5579-5586.

Beschin, A; Bilej, M; Brys, L; Torreele, E; Lucas, R; Magez, S; De Baetselier P. Convergent evolution of cytokines. Nature. 1999; 400(6745):627-628.

Lucas, R; Holmgren, L; Garcia, I; Jimenez, B; Mandriota, SJ; Borlat, F; Sim, BK; Wu, Z; Grau, GE; Shing, Y; Soff, GA; Bouck, N; Pepper MS. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood. 1998; 92(12):4730-4741.

Lucas, R; Garcia, I; Donati, YR; Hribar, M; Mandriota, SJ; Giroud, C; Buurman, WA; Fransen, L; Suter, PM; Nunez, G; Pepper, MS; Grau GE. Both TNF receptors are required for direct TNF-mediated cytotoxicity in microvascular endothelial cells. Eur J Immunol. 1998; 28(11):3577-3586.

Olivares-Fontt, EO: De Baetselier, P; Heirman, C; Thielemans, K; Lucas, R; Vray B. Effects of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha on Trypanosoma cruzi trypomastigotes. Infect Immun. 1998; 66(6):2722-2727.

Lucas, R; Juillard, P; Decoster, E; Redard, M; Burger, D; Donati, Y; Giroud, C; Monso-Hinard, C; De Kesel, T; Buurman, WA; Moore, MW; Dayer, JM; Fiers, W; Bluethmann, H; Grau GE. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol. 1997; 27(7):1719-1725.

Lou, J ; Ythier, A ; Burger, D; Zheng, L ; Juillard, P ; Lucas, R ; Dayer, JM ; Grau GE. Modulation of soluble and membrane-bound TNF-induced phenotypic and functional changes of human brain microvascular endothelial cells by recombinant TNF binding protein I. J Neuroimmunol. 1997; 77(1):107-115.

Lucas, R; Echtenacher, B; Sablon, E; Juillard, P; Magez, S; Lou, J; Donati, Y; Bosman, F; Van de Voorde, A; Fransen, L; Mannel, DN; Grau, GE; de Baetselier P. Generation of a mouse tumor necrosis factor mutant with antiperitonitis and desensitization activities comparable to those of the wild type but with reduced systemic toxicity. Infect Immun. 1997; 65(6):2006-2010.

Magez, S; Geuskens, M; Beschin, A; del Favero, H; Verschueren, H; Lucas, R; Pays, E; de Baetselier P. Specific uptake of tumor necrosis factor-alpha is involved in growth control of Trypanosoma brucei. J Cell Biol. 1997; 137(3):715-727.

Lucas, R ; Lou, JN; Juillard, P ; Moore, M ; Bluethmann, H ; Grau GE. Respective role of TNF receptors in the development of experimental cerebral malaria. J Neuroimmunol. 1997; 72(2):143-148.

Sekine-Okano, M; Lucas, R; Rungger, D; De Kesel, T; Grau, GE; Leuenberger, PM; Rungger-Brandle E. Expression and release of tumor necrosis factor-alpha by explants of mouse cornea. Invest Ophthalmol Vis Sci. 1996; 37(7):1302-1310.

Grau, GE ; Mili, N ; Lou, JN ; Morel, DR ; Ricou, B ; Lucas, R; Suter PM. Phenotypic and functional analysis of pulmonary microvascular endothelial cells from patients with acute respiratory distress syndrome. Lab Invest. 1996; 74(4):761-770.

Truyens, C; Torrico, F; Angelo-Barrios, A; Lucas, R; Heremans, H; De Baetselier, P; Carlier Y. The cachexia associated with Trypanosoma cruzi acute infection in mice is attenuated by anti-TNF-alpha, but not by anti-IL-6 or anti-IFN-gamma antibodies. Parasite Immunol. 1995; 17(11):561-568.

Garcia, I; Miyazaki, Y; Araki, K; Araki, M; Lucas, R; Grau, GE; Milon, G; Belkaid, Y; Montixi, C; Lesslauer, W and Vassalli P. Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur J Immunol. 1995; 25(8):2401-2407.

Rivera, MT ; Marques de Araujo, S ; Lucas, R ; Deman, J ; Truyens, C ; Defresne, MP ; de Baetselier, P ; Carlier Y. High tumor necrosis factor alpha (TNF-alpha) production in Trypanosoma cruzi-infected pregnant mice and increased TNF-alpha gene transcription in their offspring. Infect Immun. 1995; 63(2):591-595.

Bilej, M; Brys, L; Beschin, A ; Lucas, R; Vercauteren, E; Hanusova, R; De Baetselier P. Identification of a cytolytic protein in the coelomic fluid of Eisenia foetida earthworms. Immunol Lett. 1995; 45(1-2):123-128.

Lucas, R; Magez, S; De Leys, R; Fransen, L; Scheerlinck, JP; Rampelberg, M; Sablon, E; De Baetselier P. Mapping the lectin-like activity of tumor necrosis factor. Science. 1994; 263(5148):814-817.

Magez, S; Lucas, R; Darji, A; Songa, EB; Hamers, R; De Baetselier P. Murine tumour necrosis factor plays a protective role during the initial phase of the experimental infection with Trypanosoma brucei brucei. Parasite Immunol. 1993; 15(11):635-641.

Zanetti, G; Heumann, D; Gerain, J; Kohler, J; Abbet, P; Barras, C; Lucas, R; Glauser MP, *Baumgartner JD. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. J Immunol. 1992; 148(6):1890-1897.

Vanhaesebroeck, B; Van Bladel, S; Lenaerts, A; Suffys, P; Beyaert, R; Lucas, R; Van Roy, F; Fiers W. Two discrete types of tumor necrosis factor-resistant cells derived from the same cell line. Cancer Res. 1991; 51(9):2469-2477.

Lucas, R; Heirwegh, K; Neirynck, A; Remels, L; Van Heuverswyn, H; De Baetselier P. Generation and characterization of a neutralizing rat anti-rmTNF-alpha monoclonal antibody. Immunology. 1990; 71(2):218-223.

Invited Reviews

Lucas, R and Keisari Y. Innovative cancer therapies that combine chemotherapy or radiotherapy with immunotherapy. 2006. Recent Patents on Anti-Cancer Drug Discovery.

Lucas, R. Preclinical evaluation of a TNF-derived peptide in models of experimental pulmonary edema. 2005. Pharmaceutical Manufacturing and Packing Sourcer.

Lucas, R. Interview: Role of TNF in pulmonary edema reabsorption. 2005. Modern Aspects of Immunobiology.

Lucas, R; Kresse, M; Latta, M and Wendel A. Tumor Necrosis factor: How to make a killer molecule Tumor-specific? 2005. Current Cancer Drug Targets 5. 381-392.

Xu, J; Lucas, R and Wendel A. The potential of GM-CSF to improve resistance against infections in organ transplantation: a new tune for an old song ? Trends in Pharmacol. Sci. 2004; 25(5):254-258.

Xu, J; von Aulock, S; Lucas, R and Wendel A. Colony-stimulating factors: improvement of different anti-infectious defence mechanisms. Invited review. Current Opin. In Organ Transpl. 2004

Beschin, A; Bilej, M; Magez, S; Lucas, R and De Baetselier P. Functional convergence of invertebrate and vertebrate cytokine-like molecules based on a similar lectin-like activity. Prog Mol Subcell Biol. 2004; 34:145-163.

Hentze H, Latta M, Kuenstle G, Lucas R and Wendel A. Redox control of hepatic cell death. Toxicol. Lett. 2003; 139, 111-118.

Lucas, R; Grau, GE; Matthay, MA and Wendel A. Functional role of TNF in liver, brain and lungs. Current Trends in Immunol. 2002; 4: 47-59.

Lou, J; Lucas, R and Grau GE. Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Clin Microbiol Rev. 2001; 14(4):810-820.

Lucas, R; Lou, J; Morel, DR; Ricou, B; Suter, PM; Grau GE. TNF receptors in the microvascular pathology of acute respiratory distress syndrome and cerebral malaria. J Leukoc Biol. 1997; 61(5):551-558.

Lucas, R; Magez, S; Songa, B; Darji, A; Hamers, R; de Baetselier P. A role for TNF during African trypanosomiasis: involvement in parasite control, immunosuppression and pathology. Res Immunol. 1993; 144(5):370-376.

Darji, A; Lucas, R; Magez, S; Torreele, E; Palacios, J; Sileghem, M; Bajyana Songa, E; Hamers, R; De Baetselier P. Mechanisms underlying trypanosome-elicited immunosuppression. Ann Soc Belg Med Trop. 1992; 72 Suppl 1:27-38.

Book Chapters

Lucas R, Xu J, Braun C, Leja A, Meergans T, Hamacher J and Wendel A. Tumor Necrosis Factor in bacterial and parasitic infections: to be or not to be? In Recent Res. Devel. Infection & Immunity, 1. 2003: 303-316.

Latta M, Kresse M, Künstle G, Lucas R and Wendel A. Models of cytokine-induced hepatic failure. Disease Progression and Carcinogenesis in the Gastro-intestinal Tract, 2003. Editors, PR Galle, WE Schmidt, G. Gerken, B. Wiedenmann. Kluwer Academic Publishers.

Lucas R, Suter PM and Grau GE. TNF in the microvascular pathology of septic shock and cerebral malaria. Annual Year Book of Intensive Care and Emergency Medecine, 1997. Editor, JL Vincent. Springer Verlag.

Lucas R, Magez S, De Leys R and De Baetselier P. Cytokines: Multifunctional pathogen-specific mammalian lectins? In: Lectins: Biology, Biochemistry, Clinical Biochemistry-Volume 10, 1994. Editors, Van Driessche, Fischer, Beeckmans, Bög-Hansen., 244-249.

Patents and Inventions

LEP0682705/WO9418325: TNF muteins and a process for preparing them. Innogenetics, Belgium, Inventor

EP1105152/WO0009141: TNF-derived peptides for use in treating edema. Apeptico, Austria, Inventor

spacer
spacer
spacer
spacer spacer spacer

Education and Training

Vrije Universiteit Brussels
Ph.D. - 1993.

Vrije Universiteit Brussels
MS - 1987.

Vrije Universiteit Brussels
BS - 1984.
spacer
spacer
spacer

Research Experience & Academic Appointments

 
spacer
spacer
spacer

Society Memberships

  •  
spacer
spacer
spacer
spacer
 
white corner left spacer
spacer
spacer
spacer spacer

Copyright 2005
Medical College of Georgia
All rights reserved.

Vascular Biology Center  |  Medical College of Georgia
Please email comments, suggestions or questions to:
David Stepp, dstepp@mcg.edu.

spacer
spacer